[ZURICH] Swiss drugmaker Roche's push into personalised cancer medicines hit a milestone on Tuesday with Japanese approval of a new drug, Rozlytrek, that targets patients who must be identified...

[ZURICH] Swiss pharmaceuticals giant Roche said Monday it reached a deal worth US$4.3 billion  to buy US group Spark Therapeutics, which specialises in the development of gene therapy drugs.